Core Viewpoint - Kiniksa Pharmaceuticals International, plc (KNSA) has seen a 15% increase in share price over the past four weeks, closing at $33.38, with analysts suggesting a potential upside of 26.7% based on a mean price target of $42.29 [1][12]. Price Targets and Analyst Consensus - The average price target for KNSA is derived from seven short-term estimates, ranging from a low of $32.00 to a high of $55.00, with a standard deviation of $8.96, indicating variability in analyst predictions [2]. - The lowest estimate suggests a decline of 4.1%, while the highest indicates a potential upside of 64.8% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding KNSA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has increased by 39.2% over the past month, with three estimates revised upward and no negative revisions [12]. - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Price Movement Implications - While consensus price targets may not reliably predict the extent of KNSA's gains, the implied direction of price movement appears to be a useful guide for investors [14].

Core Viewpoint - The sustainability of a trend is crucial for successful short-term investing, and confirming fundamental factors is essential to maintain momentum in stocks [1][2]. Group 1: Trend Analysis - Timing entries into a trend significantly impacts investment success, as trends can reverse unexpectedly, leading to potential losses [1][2]. - A predefined screening strategy, "Recent Price Strength," helps identify stocks with strong fundamentals that can sustain their upward trends [3]. Group 2: Company Spotlight - Kiniksa Pharmaceuticals International, plc (KNSA) - KNSA has shown a solid price increase of 24.1% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also increased by 15% in the last four weeks, suggesting that the upward trend is still intact [5]. - KNSA is trading at 96.3% of its 52-week high-low range, indicating a potential breakout [5]. Group 3: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, underscoring the effectiveness of this ranking system [7]. Group 4: Investment Opportunities - In addition to KNSA, there are other stocks that meet the criteria of the "Recent Price Strength" screen, providing additional investment opportunities [8]. - The Zacks Premium Screens offer over 45 strategically created options to help investors find winning stock picks based on their personal investing styles [8].

Market Overview - U.S. stock markets have continued to rise in early August despite trade uncertainties and the Federal Reserve's indecision regarding interest rate cuts in 2025 [1][2] - The outcome of the Fed's annual Jackson Hole Symposium, scheduled for August 21-23, is anticipated to be significant [2] Stock Performance - Few stocks have demonstrated price strength, with a focus on those recently experiencing a bull run [3] - Five highlighted stocks include Modine Manufacturing Co. (MOD), Tutor Perini Corp. (TPC), Kiniksa Pharmaceuticals International plc (KNSA), Life360 Inc. (LIF), and Euroseas Ltd. (ESEA) [3] Stock Screening Criteria - Stocks must show a percentage change in price greater than zero over the last four weeks and greater than 10% over the last twelve weeks [5] - Zacks Rank 1 (Strong Buy) and an average broker rating of 1 are also key indicators of potential performance [6] - Stocks must be trading at a minimum price of $5 and be near their 52-week highs, with a current price/52-week high-low range greater than 85% [7] Individual Stock Highlights - **Modine Manufacturing (MOD)**: Stock price increased by 46.1% in four weeks, with an expected earnings growth rate of 14.3% for the current year [8][10] - **Tutor Perini (TPC)**: Stock price surged 14.3% in four weeks, with an expected earnings growth rate exceeding 100% for the current year [14] - **Kiniksa Pharmaceuticals (KNSA)**: Stock price climbed 13.7% in four weeks, with expected earnings growth over 100% for the current year [15] - **Life360 (LIF)**: Stock price advanced 8.3% in four weeks, with expected earnings growth over 100% for the current year [17] - **Euroseas (ESEA)**: Stock price gained 2.8% in four weeks, with an expected earnings growth rate of 4% for the current year [19]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc (KNSA) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Characteristics - Momentum investing focuses on following a stock's recent price trends, with the strategy of buying high with the hope of selling even higher [1]. - KNSA's shares have increased by 21.46% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 5.78% during the same period [6]. - Over the past quarter, KNSA's shares have risen by 22.76%, and they are up 36.67% over the last year, significantly outperforming the S&P 500, which has moved 11.71% and 19.86% respectively [7]. Trading Volume - KNSA's average 20-day trading volume is 671,315 shares, which is considered a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the last two months, two earnings estimates for KNSA have been revised upwards, with the consensus estimate increasing from $0.74 to $0.94 [10]. - For the next fiscal year, two estimates have also moved upwards, with no downward revisions noted [10]. Conclusion - Given the strong momentum indicators and positive earnings outlook, KNSA is positioned as a promising investment opportunity [12].

Core Viewpoint - Kiniksa Pharmaceuticals International, plc (KNSA) is experiencing solid improvements in earnings estimates, which may lead to continued short-term price momentum and a favorable investment opportunity [1][10]. Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism regarding Kiniksa's earnings prospects, which is expected to positively influence its stock price [2]. - The current-quarter earnings estimate of $0.29 per share indicates a significant increase of +261.1% compared to the previous year, with a 36.51% rise in the Zacks Consensus Estimate over the last 30 days due to two upward revisions [5][6]. - For the full year, Kiniksa is projected to earn $0.94 per share, representing a +256.7% change from the prior year, with a 26.58% increase in the consensus estimate over the past month [6][7]. Zacks Rank - Kiniksa currently holds a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on favorable estimate revisions [8]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting a robust track record of success [3][9]. Stock Performance - The stock has gained 8.5% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects, making it a candidate for portfolio consideration [10].

Group 1 - Kiniksa Pharmaceuticals International, plc (KNSA) closed at $30.26, with an 8.5% gain over the past four weeks, and a mean price target of $41.14 suggests a 36% upside potential [1] - The mean estimate includes seven short-term price targets with a standard deviation of $7.45, indicating variability among analysts; the lowest estimate is $32.00 (5.8% increase), while the highest is $54.00 (78.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with a 26.6% increase in the Zacks Consensus Estimate for the current year, indicating potential upside for KNSA [11][12] Group 2 - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful starting point for further research into the stock's fundamental drivers [10][14]

Core Viewpoint - The sustainability of a stock trend is crucial for successful short-term investing, and various factors must be considered to maintain momentum in stock prices [1][2]. Group 1: Stock Performance - Kiniksa Pharmaceuticals International, plc (KNSA) has shown a solid price increase of 13.3% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also increased by 8.5% in the last four weeks, suggesting that the upward trend is still intact [5]. - KNSA is currently trading at 88.2% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting strong optimism from the brokerage community regarding its near-term price performance [7]. - The Zacks Rank system has a proven track record, with Rank 1 stocks generating an average annual return of +25% since 1988 [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like KNSA that have the fundamental strength to maintain their upward trend [3]. - There are additional stocks that meet the criteria of the "Recent Price Strength" screen, providing further investment opportunities [8]. - The effectiveness of stock-picking strategies can be backtested using the Zacks Research Wizard, which includes successful stock-picking strategies [9].

[PART I — FINANCIAL INFORMATION](index=7&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited financials show total assets grew to **$661.2 million**, with H1 2025 net income of **$26.4 million** from ARCALYST revenue [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) Total assets increased to **$661.2 million** by June 30, 2025, with shareholders' equity at **$495.0 million**, driven by cash and inventory Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $192,037 | $183,581 | | Inventory | $48,181 | $26,364 | | Total current assets | $420,311 | $331,799 | | Total assets | $661,150 | $580,553 | | **Liabilities & Equity** | | | | Total current liabilities | $117,827 | $100,621 | | Total liabilities | $166,143 | $142,117 | | Total shareholders' equity | $495,007 | $438,436 | [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=8&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) H1 2025 saw net income of **$26.4 million**, a turnaround from loss, with total revenue at **$294.6 million** from ARCALYST sales Statement of Operations Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $156,797 | $108,631 | $294,582 | $188,489 | | Income (Loss) from Operations | $20,160 | $(117) | $33,432 | $(16,659) | | Net Income (Loss) | $17,832 | $(3,908) | $26,371 | $(21,612) | | Diluted EPS | $0.23 | $(0.06) | $0.34 | $(0.31) | - The shift from a net loss to net income was primarily driven by a **52% YoY increase** in net product revenue for Q2 and a **61% YoY increase** for H1 2025[22](index=22&type=chunk) [Consolidated Statements of Cash Flows](index=10&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow improved to **$50.4 million** for H1 2025, increasing cash and cash equivalents by **$8.5 million** overall Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $50,414 | $9,155 | | Net cash used in investing activities | $(55,424) | $(21,273) | | Net cash provided by financing activities | $13,466 | $3,435 | | **Net increase (decrease) in cash** | **$8,456** | **$(8,683)** | [Notes to Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Notes detail accounting policies, UK redomiciliation, ARCALYST growth, mavrilimumab termination, and manufacturing commitments - The company completed its redomiciliation from Bermuda to the United Kingdom in June 2024, becoming Kiniksa Pharmaceuticals International, plc[29](index=29&type=chunk) - As of June 30, 2025, the company had cash, cash equivalents, and short-term investments of **$307.8 million** and believes these funds are sufficient for at least the next twelve months of operations[35](index=35&type=chunk) - The company has total manufacturing purchase commitments of **$161.6 million**, with **$136.7 million** related to the ARCALYST technology transfer and supply agreement with Samsung[126](index=126&type=chunk)[202](index=202&type=chunk) - In April 2025, the company and Huadong mutually terminated their collaboration agreement for mavrilimumab[70](index=70&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes strong H1 2025 performance to ARCALYST success, with net product revenue up **61%** to **$294.6 million**, yielding **$26.4 million** net income - The company's primary commercial product is ARCALYST®, an IL-1α and IL-1β cytokine trap approved for recurrent pericarditis and other rare diseases. The pipeline is focused on cardiovascular indications, including KPL-387 for recurrent pericarditis[137](index=137&type=chunk)[138](index=138&type=chunk) - Development of abiprubart was discontinued in February 2025, and the company is exploring strategic alternatives for the asset. The license agreement for mavrilimumab was also terminated[140](index=140&type=chunk)[142](index=142&type=chunk) Financial Results Comparison (Six Months Ended June 30) | Metric (in millions) | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Product revenue, net | $294.6 | $182.3 | +$112.3 | | Total revenue | $294.6 | $188.5 | +$106.1 | | R&D Expenses | $38.1 | $50.4 | -$12.3 | | SG&A Expenses | $90.4 | $81.1 | +$9.3 | | Net Income (Loss) | $26.4 | $(21.6) | +$48.0 | - The company believes its cash, cash equivalents, and short-term investments of **$307.8 million** as of June 30, 2025, are sufficient to fund operations and capital expenditures for at least the next 12 months[145](index=145&type=chunk)[201](index=201&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Market risk exposure primarily relates to interest rate sensitivities on short-term investments, with no material changes reported - The company's primary market risk exposure is interest rate sensitivity on its short-term investments. No material changes were reported for the quarter[218](index=218&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[220](index=220&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[221](index=221&type=chunk) [PART II — OTHER INFORMATION](index=44&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company is not a party to any material legal proceedings and has no litigation contingency reserves - The company is not currently a party to any material legal proceedings[224](index=224&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) Key risks include ARCALYST commercialization, pricing, clinical development, third-party manufacturing, and IP protection [Risks Related to Commercialization](index=44&type=section&id=Risks%20Related%20to%20Commercialization) ARCALYST commercial success faces risks in revenue growth, specialty pharmacy reliance, and favorable third-party payor reimbursement - Continued commercialization of ARCALYST is subject to risks including manufacturing sufficiency, prescriber adoption, and competition, which could impair revenue generation[227](index=227&type=chunk)[228](index=228&type=chunk) - Successful commercialization depends on third-party payors providing favorable coverage and reimbursement, which is subject to cost-control efforts and potential restrictions[234](index=234&type=chunk)[235](index=235&type=chunk) - The market opportunity for ARCALYST and other product candidates may be smaller than estimated, which could adversely affect revenue and profitability if the addressable patient population is lower than projected[249](index=249&type=chunk)[250](index=250&type=chunk) [Risks Related to Product Development](index=58&type=section&id=Risks%20Related%20to%20Product%20Development) Product development faces risks: lengthy, expensive clinical trials, uncertain outcomes, enrollment challenges, and potential undesirable side effects - Clinical drug development is a long, costly process with uncertain outcomes. The company may face substantial delays or fail to demonstrate the required safety and efficacy for its product candidates[288](index=288&type=chunk) - Enrolling a sufficient number of patients in clinical trials is challenging, particularly for rare diseases, and difficulties in enrollment could delay or prevent trial completion[303](index=303&type=chunk) - Undesirable side effects or safety risks from product candidates could delay or prevent regulatory approval, lead to a more restrictive label, or result in market withdrawal after approval[306](index=306&type=chunk) [Risks Related to Manufacturing and Our Reliance on Third Parties](index=68&type=section&id=Risks%20Related%20to%20Manufacturing%20and%20Our%20Reliance%20on%20Third%20Parties) Reliance on third-party CDMOs creates supply, cost, and quality risks, especially with the complex ARCALYST technology transfer to Samsung - The company relies on third-party CDMOs for manufacturing, which increases the risk of insufficient quantities, unacceptable costs or quality, and potential delays to development and commercialization[347](index=347&type=chunk) - A technology transfer of ARCALYST drug substance manufacturing from Regeneron to Samsung is underway and is subject to significant risks, including potential delays, comparability issues, and the need for FDA approval[367](index=367&type=chunk)[368](index=368&type=chunk)[369](index=369&type=chunk) - The company depends on single-source suppliers for critical components of ARCALYST and its pipeline candidates. The loss of any of these suppliers could significantly harm the business[375](index=375&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=107&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities,%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) No unregistered sales of equity, use of proceeds, or issuer purchases of equity securities were reported - None reported[575](index=575&type=chunk) [Defaults Upon Senior Securities](index=107&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported - None reported[576](index=576&type=chunk) [Mine Safety Disclosures](index=107&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None reported[577](index=577&type=chunk) [Other Information](index=107&type=section&id=Item%205.%20Other%20Information) The company disclosed the adoption of Rule 10b5-1 trading arrangements by two officers during Q2 2025 Adoption of Trading Arrangements by Officers | Name | Title | Action | Effective Date | Maximum Shares in Plan | | :--- | :--- | :--- | :--- | :--- | | Sanj K. Patel | CEO and Chairman | Adoption | May 7, 2025 | 355,590 | | Michael R. Megna | SVP, Finance and CAO | Adoption | May 24, 2025 | 36,145 | [Exhibits](index=108&type=section&id=Item%206.%20Exhibits) Exhibits filed with Form 10-Q include incentive plan documents, a consulting agreement, and officer certifications - The report includes exhibits such as the KPL-387 Long-Term Incentive Plan, related award agreements, a consulting agreement, and certifications by the CEO and CFO[580](index=580&type=chunk)

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $156.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.92%. This compares to year-ago revenues of $108.63 million. The company has topped consensus revenue estimates four times over the last four quarters. Kiniksa Pharmaceuticals International, plc ( ...

Financial Data and Key Metrics Changes - Kynixa reported net revenue of $156.8 million in Q2 2025, representing a growth of $19 million over Q1 2025 and a 52% year-over-year increase compared to Q2 2024 [6][11][17] - The company raised its full-year 2025 net sales guidance for Arclis to between $625 million and $640 million, up from the previous range of $590 million to $600 million [7][17] - Net income for Q2 2025 was $17.8 million, compared to a net loss of $3.9 million in the same quarter last year [19] Business Line Data and Key Metrics Changes - Arclis revenue grew 52% year-over-year in Q2 2025, driven by strong growth in new patient enrollments and prescribers [11][19] - The average duration of therapy for patients on Arclis was approximately 30 months, with patient compliance remaining strong at over 85% [13][55] Market Data and Key Metrics Changes - The penetration into the multiple recurrence population increased from approximately 13% at the end of 2024 to approximately 15% at the end of Q2 2025 [12][26] - Approximately 20% of total prescriptions for Arclis were from patients on their first recurrence, indicating a growing acceptance among healthcare professionals to prescribe early in the disease [14][28] Company Strategy and Development Direction - Kynixa is committed to maximizing the potential of Arclis and advancing its clinical portfolio, including the development of KPL-387, a liquid formulation IL-1 receptor antagonist [9][21] - The company aims to drive additional innovation for patients with recurrent pericarditis and maintain its leadership position in the market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of Arclis, highlighting the strong commercial execution and the potential for future launches of novel therapies [18][21] - The company remains focused on creating value while maintaining a cash flow positive operating plan [19][57] Other Important Information - Kynixa's cash balance increased by approximately $40 million to $307.8 million in Q2 2025, supporting ongoing investments without needing to access capital markets [19] - The company has initiated a phase two-three clinical trial for KPL-387, with data expected in the second half of next year [9][10] Q&A Session Summary Question: Trends in first recurrence setting for Arclis - Management noted a significant opportunity in the first recurrence group, with around 20% of total prescriptions coming from this setting, reflecting increased confidence among healthcare professionals [24][26] Question: Patient drop-off and new start outlook for KPL-387 - Management indicated that patients are staying on therapy for an average of 30 months, with compliance over 85%, suggesting a positive outlook for KPL-387 [32][34] Question: Expansion of sales force and marketing strategies - Management is exploring further expansion of the sales force and innovative marketing strategies, including digital marketing and AI targeting [39][42][46] Question: Efficacy expectations for KPL-387 - Management stated that the efficacy profile for KPL-387 will be data-driven, with a focus on optimizing performance through the trial design [68][70] Question: Emerging competition in the market - Management acknowledged the presence of potential oral competitors but emphasized Kynixa's leadership in understanding the disease mechanism and the importance of IL-1 inhibition [68][70]